abstract: UNASSIGNED: @entity1 is an incapacitating condition commonly affecting cochlear implant (CI) candidates. The aim of this clinical study is to assess the long-term effects of CI treatment in @entity0 with severe-to-profound, sensorineural, @entity2 ( @entity2 ) and incapacitating @entity1 . We performed a prospective Cochlear    company-sponsored multicentre study in five Spanish centres. Sixteen @entity0 with @entity2 and incapacitating @entity1 , which was indicated by a @entity3 Inventory (THI) score >58%, received a Nucleus   CI in their deaf ear. The study design includes repeated within-subject measures on hearing, @entity1 , @entity6 and quality of life up to 12 months after initial CI fitting. In addition to @entity2 and @entity1 , all @entity0 suffered from @entity6 . Most @entity0 had a @entity5 and received a CI within 2 years after their @entity2 . Preliminary 6-month, post-CI activation data of 13 subjects showed that the majority of @entity0 perceived a subjective benefit from CI treatment, which was assessed using the THI, a Visual Analogue Scale of @entity1 loudness/annoyance and the Speech, Spatial and Qualities of Hearing Scale. Preliminary 12-month data of 7 subjects showed that most @entity0 also perceived a degree of relief from their @entity6 . One @entity0 showed no improvements in any of the applied scales, which could be explained by partial insertion of the electrode due to obstruction of the cochlea by @entity7 . In conclusion, CI can successfully be used in the treatment of @entity2 @entity0 with accompanying severe @entity1 and @entity6 . Implantation resulted in hearing benefits and a durable relief from @entity1 and @entity6 in the majority of @entity0 . These findings support the hypothesis that pathophysiological mechanisms after peripheral @entity4 are at least partly reversible when hearing is restored with a CI.    2015 S. Karger AG, Basel.

title: Cochlear Implants as a Treatment Option for Unilateral Hearing Loss, Severe @entity1 and XXXX .

answer: @entity6


abstract: AIM: To evaluate the technical success and mid-term outcomes following transcatheter  embolisation  of type 1a endoleak after Nellix endovascular @entity1 sealing (EVAS). MATERIALS AND METHODS: Seven @entity0 (5 @entity0 ; mean age 83; range 79-90) underwent transcatheter embolisation between July 2013 and August 2014. The average time from EVAS to embolisation was 136  days (range 6-301) and from endoleak diagnosis to embolisation was 20  days (range 2-50). Embolisation  was performed with coils and Onyx in six cases and Onyx only in one case. Technical success, imaging and clinical outcomes of embolisation were reviewed. Technical success was defined as elimination of the endoleak on completion angiography and first imaging follow-up. Clinical success was defined as unchanged or decreased @entity1 sac size on subsequent follow-up (average 8  months; range 103-471  days). RESULTS: All cases were technically successful. One @entity0 required a second endovascular procedure following Onyx reflux into the Nellix endograft and another @entity0 required surgical closure of a brachial puncture site. All @entity0 are endoleak free with stable sac size on the latest available follow-up imaging. CONCLUSION: If a type 1 endoleak occurs after EVAS, embolisation using Onyx with or without coils is feasible and effective with high technical success and freedom from endoleak recurrence at mid-term follow-up.

title: Transcatheter Embolisation of Proximal Type 1 Endoleaks Following Endovascular XXXX (EVAS) Using the Nellix Device: Technique and Outcomes.

answer: @entity1


abstract: OBJECTIVE: To evaluate the prognostic factors affecting survival in @entity3 ( @entity3 ) @entity0 with pathologic T0 (ypT0) underwent preoperative radiotherapy. @entity0 AND METHODS: Two hundred and ninety-six @entity0 with @entity3 who had received preoperative radiotherapy from 1980 to 2007 were retrospectively analyzed. One hundred @entity0 were ypT0 after preoperative radiotherapy. Univariate and multivariate analyses were performed to evaluate the predictive impact of residual lymph node status on @entity2 ( @entity2 ) and progression-free survival (PFS). RESULTS: Among the originally analyzed 296 @entity0 , 100 (33.7  %) @entity0 had ypT0, including 78 @entity0 (78  %) with ypT0N0, and 22 @entity0 (22  %) with ypT0N1. The 5-year @entity2 of the total @entity0 was 42.4  %. @entity0 with ypT0N0 have significant improved 5-year @entity2 and PFS than ypT0N1 @entity0 ( @entity2 : 50.7  % vs 13.6  %, P   =   0.004; PFS: 49.6  % vs 13.6  %, P   =   0.003). In multivariate analysis, residual lymph node status was also an independent prognostic factors for @entity2 (HR: 0.406, 95  % CI: 0.240-0.686, P   =   0.001) and PFS (HR: 0.427, 95  % CI: 0.248-0.734, P   =   0.002). CONCLUSION: Our results indicate that @entity0 with ypT0N0 after preoperative radiotherapy had significantly better @entity2 and PFS than @entity0 with ypT0N1 in @entity3 . Residual nodal metastasis of @entity3 @entity0 with pathological complete response of the @entity1 after neoadjuvant radiotherapy does influence prognosis.

title: Residual lymph node status is an independent prognostic factor in XXXX with pathologic T0 after preoperative radiotherapy.

answer: @entity3


abstract: OBJECTIVES: To evaluate the utility of @entity1 PET in re-staging and response assessment of @entity0 who underwent definitive treatment for @entity2 ( @entity2 ). METHODS AND MATERIALS: A retrospective review of @entity0 undergoing @entity3 -FDG PET imaging for @entity2 between January 1997 and October 2010 at the Peter MacCallum Cancer Centre with follow-up until February 2015 was performed. Data analysis was performed on @entity0 who were treated definitively and had post treatment PET imaging performed either as a re-staging scan for ongoing monitoring, suspicion of recurrence or assessment for suitability of salvage treatment or for response assessment within 1-6 months of treatment. Management plans were recorded prospectively prior to @entity1 PET imaging and compared to post imaging management to assess impact of the study as per our previously defined categories: "high" if the primary treatment modality or intent was changed; "medium" if the radiotherapy technique or dose was altered. In total, 62 @entity0 were included in the analysis. Thirty-six @entity0 had 53 restaging scans and 37 @entity0 had a response assessment scan. The median follow up of @entity0 in the re-staging group was 5.3 years (95% CI [4.6-9.4]), while it was 5.7 years (95% CI [4.3-10.8]) in the response assessment group. RESULTS: Re-staging @entity1 PET scans had a high impact in 24 of 53 cases (45%) and a medium impact in 6 of 53 cases (11%). In the response assessment group, 24 of 37 @entity0 had a complete metabolic response (CMR). @entity0 without a CMR had a 15% 1-year overall survival (95% CI 0.04-0.55). Those with a CMR had an 88% 2-year overall survival (95% CI 0.75-1.00) and a 68% 5-year overall survival (95% CI 0.49-0.95). Presence of a CMR (p<0.001) and nodal involvement (P = 0.016) were statistically significant prognostic factors for overall survival. CONCLUSION: @entity1 PET imaging had a high impact on restaging following definitive treatment in @entity0 with @entity2 . Metabolic response was significantly associated with overall survival. @entity1 PET may play an important role in ongoing post treatment management of @entity2 .

title: 15-year Experience of 18F-FDG PET Imaging in Response Assessment and Re-staging after Definitive XXXX .

answer: @entity2


abstract: UNASSIGNED: Study Design Randomized controlled trial. Objectives To determine if thoracic spinal manipulative therapy (SMT) alters thoracic kinematics, thoracic excursion, and scapular kinematics compared to a sham-SMT in @entity0 with @entity1 , and also to compare changes in @entity0 -reported outcomes between treatment groups. Background Prior studies indicate that thoracic SMT can improve @entity1 in individuals with @entity1 . However, the mechanisms underlying these benefits are not well understood. Methods @entity0 with @entity3 (n=52) were randomly assigned to receive a single session of thoracic SMT or sham-SMT. @entity2 and scapular kinematics during active arm elevation and overall thoracic excursion were measured before and after the intervention. @entity0 -reported outcomes measured were: @entity1 ( @entity1 rating scale [NPRS]), function (Pennsylvania Shoulder Score [Penn]), and global rating of change (GROC). Results There were no significant differences between groups in changes post-intervention for thoracic kinematics or excursion, shoulder kinematics, or @entity0 -reported outcomes (P>.05). Both groups showed an increase in scapular internal rotation during arm raising (mean of 0.9  , 95% CI [0.3  , 1.6  ], P=.003) and lowering (0.8  , 95% CI [0.0  , 1.5  ], P=.041), as well as improved NPRS (1.2 points, 95% CI [0.3, 1.8], P<.001) and Penn (9.1 points, 95% CI [6.5, 11.7], P<.001) scores. Conclusion @entity2 spine extension and excursion did not change significantly following thoracic SMT. There were small, but likely not clinically meaningful changes in scapular internal rotation in both groups. @entity0 -reported @entity1 and function improved in both groups, however there were no significant differences in the changes between the SMT and the sham-SMT groups. Overall, @entity0 -reported outcomes improved in both groups without meaningful changes to thoracic or scapular motion. Level of Evidence Therapy, level 1b-. J Orthop Sports Phys Ther, Epub 21 May 2015. doi:10.2519/jospt.2015.5647.

title: @entity2 Spine Manipulation in Individuals With @entity3 Does Not Immediately Alter @entity2 Spine Kinematics, XXXX Excursion, or Scapular Kinematics: A Randomized Controlled Trial.

answer: @entity2


abstract: UNASSIGNED: Study Design Randomized controlled trial. Objectives To determine if thoracic spinal manipulative therapy (SMT) alters thoracic kinematics, thoracic excursion, and scapular kinematics compared to a sham-SMT in @entity0 with @entity1 , and also to compare changes in @entity0 -reported outcomes between treatment groups. Background Prior studies indicate that thoracic SMT can improve @entity1 in individuals with @entity1 . However, the mechanisms underlying these benefits are not well understood. Methods @entity0 with @entity3 (n=52) were randomly assigned to receive a single session of thoracic SMT or sham-SMT. @entity2 and scapular kinematics during active arm elevation and overall thoracic excursion were measured before and after the intervention. @entity0 -reported outcomes measured were: @entity1 ( @entity1 rating scale [NPRS]), function (Pennsylvania Shoulder Score [Penn]), and global rating of change (GROC). Results There were no significant differences between groups in changes post-intervention for thoracic kinematics or excursion, shoulder kinematics, or @entity0 -reported outcomes (P>.05). Both groups showed an increase in scapular internal rotation during arm raising (mean of 0.9  , 95% CI [0.3  , 1.6  ], P=.003) and lowering (0.8  , 95% CI [0.0  , 1.5  ], P=.041), as well as improved NPRS (1.2 points, 95% CI [0.3, 1.8], P<.001) and Penn (9.1 points, 95% CI [6.5, 11.7], P<.001) scores. Conclusion @entity2 spine extension and excursion did not change significantly following thoracic SMT. There were small, but likely not clinically meaningful changes in scapular internal rotation in both groups. @entity0 -reported @entity1 and function improved in both groups, however there were no significant differences in the changes between the SMT and the sham-SMT groups. Overall, @entity0 -reported outcomes improved in both groups without meaningful changes to thoracic or scapular motion. Level of Evidence Therapy, level 1b-. J Orthop Sports Phys Ther, Epub 21 May 2015. doi:10.2519/jospt.2015.5647.

title: XXXX Spine Manipulation in Individuals With @entity3 Does Not Immediately Alter @entity2 Spine Kinematics, @entity2 Excursion, or Scapular Kinematics: A Randomized Controlled Trial.

answer: @entity2


abstract: UNASSIGNED: Study Design Randomized controlled trial. Objectives To determine if thoracic spinal manipulative therapy (SMT) alters thoracic kinematics, thoracic excursion, and scapular kinematics compared to a sham-SMT in @entity0 with @entity1 , and also to compare changes in @entity0 -reported outcomes between treatment groups. Background Prior studies indicate that thoracic SMT can improve @entity1 in individuals with @entity1 . However, the mechanisms underlying these benefits are not well understood. Methods @entity0 with @entity3 (n=52) were randomly assigned to receive a single session of thoracic SMT or sham-SMT. @entity2 and scapular kinematics during active arm elevation and overall thoracic excursion were measured before and after the intervention. @entity0 -reported outcomes measured were: @entity1 ( @entity1 rating scale [NPRS]), function (Pennsylvania Shoulder Score [Penn]), and global rating of change (GROC). Results There were no significant differences between groups in changes post-intervention for thoracic kinematics or excursion, shoulder kinematics, or @entity0 -reported outcomes (P>.05). Both groups showed an increase in scapular internal rotation during arm raising (mean of 0.9  , 95% CI [0.3  , 1.6  ], P=.003) and lowering (0.8  , 95% CI [0.0  , 1.5  ], P=.041), as well as improved NPRS (1.2 points, 95% CI [0.3, 1.8], P<.001) and Penn (9.1 points, 95% CI [6.5, 11.7], P<.001) scores. Conclusion @entity2 spine extension and excursion did not change significantly following thoracic SMT. There were small, but likely not clinically meaningful changes in scapular internal rotation in both groups. @entity0 -reported @entity1 and function improved in both groups, however there were no significant differences in the changes between the SMT and the sham-SMT groups. Overall, @entity0 -reported outcomes improved in both groups without meaningful changes to thoracic or scapular motion. Level of Evidence Therapy, level 1b-. J Orthop Sports Phys Ther, Epub 21 May 2015. doi:10.2519/jospt.2015.5647.

title: @entity2 Spine Manipulation in Individuals With @entity3 Does Not Immediately Alter XXXX Spine Kinematics, @entity2 Excursion, or Scapular Kinematics: A Randomized Controlled Trial.

answer: @entity2


abstract: UNASSIGNED: Study Design Randomized controlled trial. Objectives To determine if thoracic spinal manipulative therapy (SMT) alters thoracic kinematics, thoracic excursion, and scapular kinematics compared to a sham-SMT in @entity0 with @entity1 , and also to compare changes in @entity0 -reported outcomes between treatment groups. Background Prior studies indicate that thoracic SMT can improve @entity1 in individuals with @entity1 . However, the mechanisms underlying these benefits are not well understood. Methods @entity0 with @entity3 (n=52) were randomly assigned to receive a single session of thoracic SMT or sham-SMT. @entity2 and scapular kinematics during active arm elevation and overall thoracic excursion were measured before and after the intervention. @entity0 -reported outcomes measured were: @entity1 ( @entity1 rating scale [NPRS]), function (Pennsylvania Shoulder Score [Penn]), and global rating of change (GROC). Results There were no significant differences between groups in changes post-intervention for thoracic kinematics or excursion, shoulder kinematics, or @entity0 -reported outcomes (P>.05). Both groups showed an increase in scapular internal rotation during arm raising (mean of 0.9  , 95% CI [0.3  , 1.6  ], P=.003) and lowering (0.8  , 95% CI [0.0  , 1.5  ], P=.041), as well as improved NPRS (1.2 points, 95% CI [0.3, 1.8], P<.001) and Penn (9.1 points, 95% CI [6.5, 11.7], P<.001) scores. Conclusion @entity2 spine extension and excursion did not change significantly following thoracic SMT. There were small, but likely not clinically meaningful changes in scapular internal rotation in both groups. @entity0 -reported @entity1 and function improved in both groups, however there were no significant differences in the changes between the SMT and the sham-SMT groups. Overall, @entity0 -reported outcomes improved in both groups without meaningful changes to thoracic or scapular motion. Level of Evidence Therapy, level 1b-. J Orthop Sports Phys Ther, Epub 21 May 2015. doi:10.2519/jospt.2015.5647.

title: @entity2 Spine Manipulation in Individuals With XXXX Does Not Immediately Alter @entity2 Spine Kinematics, @entity2 Excursion, or Scapular Kinematics: A Randomized Controlled Trial.

answer: @entity3


abstract: Measurements of serum @entity5 (hTg) were performed using a specific radioimmunoassay. Sera with detectable anti- @entity5 (anti-Tg) antibody titers (> or = 1:10) as assessed by passive hemagglutination were discarded. Assays were carried out under conditions in which anti-Tg titers less than 1:10 produced no interference. The assay sensitivity was 1.25 ng/ml and the mean +/- SE concentration of serum hTg in 58 control subjects was 9.5 +/- 0.9 ng/ml (range < 1.25-27 ng/ml). A slight but significant (p < 0.025) increase in the mean hTg level was observed in 12 pregnant @entity0 at delivery (25.7 +/- 5.2 ng/ml). Moderate to marked elevations of serum hTg were observed in @entity0 with @entity7 (61.4 +/- 15 ng/ml; n = 23), @entity6 (138 +/- 67 ng/ml; n = 5), toxic @entity4 (129 +/- 47 ng/ml; n = 13), untreated (424 +/- 101 ng/ml; n = 35) or treated (328 +/- 222 ng/ml; n = 14) toxic @entity7 . 88 @entity0 with @entity3 and 10 with @entity1 were studied. The mean level of serum hTg was increased in untreated @entity3 (89.5 +/- 19 ng/ml; n = 13) but not in undifferentiated (10 +/- 2.9 ng/ml; n = 6) or medullary (0.8 +/- 0.2 ng/ml; = 3) @entity2 . In treated @entity3 the mean hTg levels were normal (8.2 +/- 0.2 ng/ml) in @entity0 (n = 24) with no evidence of either a thyroid residue or metastatic disease, moderately increased (56.6 +/- 16 ng/ml) in @entity0 (n = 27) with residual thyroid tissue, markedly elevated in @entity0 with lymph node metastases (199 +/- 50 ng/ml; n = 5) and extremely elevated in those with bone (4004 +/- 982 ng/ml; n = 8) or lung (2520 +/- 620 ng/ml; n = 5) metastases. There was no significant difference in serum hTg between functioning (n = 23) and nonfunctioning (n = 5) metastases as assessed by 131I whole body scan. A slight but significant (p < 0.0005) increase in the mean concentration of hTg was observed in @entity1 (21.7 +/- 4.5 ng/ml; n = 10). Serial measurements showed a transient increase of serum hTg after 131I therapy of @entity3 , toxic @entity7 or toxic @entity4 , with peak values usually occurring within the first three days. A fall of serum hTg after administration of suppressive doses of thyroid hormone to @entity0 with @entity7 and a rise after discontinuation of thyroid suppressive therapy in @entity0 with metastatic @entity3 was observed.(ABSTRACT TRUNCATED AT 400 WORDS)

title: Serum @entity5 in XXXX and other thyroid disorders.

answer: @entity3


abstract: Measurements of serum @entity5 (hTg) were performed using a specific radioimmunoassay. Sera with detectable anti- @entity5 (anti-Tg) antibody titers (> or = 1:10) as assessed by passive hemagglutination were discarded. Assays were carried out under conditions in which anti-Tg titers less than 1:10 produced no interference. The assay sensitivity was 1.25 ng/ml and the mean +/- SE concentration of serum hTg in 58 control subjects was 9.5 +/- 0.9 ng/ml (range < 1.25-27 ng/ml). A slight but significant (p < 0.025) increase in the mean hTg level was observed in 12 pregnant @entity0 at delivery (25.7 +/- 5.2 ng/ml). Moderate to marked elevations of serum hTg were observed in @entity0 with @entity7 (61.4 +/- 15 ng/ml; n = 23), @entity6 (138 +/- 67 ng/ml; n = 5), toxic @entity4 (129 +/- 47 ng/ml; n = 13), untreated (424 +/- 101 ng/ml; n = 35) or treated (328 +/- 222 ng/ml; n = 14) toxic @entity7 . 88 @entity0 with @entity3 and 10 with @entity1 were studied. The mean level of serum hTg was increased in untreated @entity3 (89.5 +/- 19 ng/ml; n = 13) but not in undifferentiated (10 +/- 2.9 ng/ml; n = 6) or medullary (0.8 +/- 0.2 ng/ml; = 3) @entity2 . In treated @entity3 the mean hTg levels were normal (8.2 +/- 0.2 ng/ml) in @entity0 (n = 24) with no evidence of either a thyroid residue or metastatic disease, moderately increased (56.6 +/- 16 ng/ml) in @entity0 (n = 27) with residual thyroid tissue, markedly elevated in @entity0 with lymph node metastases (199 +/- 50 ng/ml; n = 5) and extremely elevated in those with bone (4004 +/- 982 ng/ml; n = 8) or lung (2520 +/- 620 ng/ml; n = 5) metastases. There was no significant difference in serum hTg between functioning (n = 23) and nonfunctioning (n = 5) metastases as assessed by 131I whole body scan. A slight but significant (p < 0.0005) increase in the mean concentration of hTg was observed in @entity1 (21.7 +/- 4.5 ng/ml; n = 10). Serial measurements showed a transient increase of serum hTg after 131I therapy of @entity3 , toxic @entity7 or toxic @entity4 , with peak values usually occurring within the first three days. A fall of serum hTg after administration of suppressive doses of thyroid hormone to @entity0 with @entity7 and a rise after discontinuation of thyroid suppressive therapy in @entity0 with metastatic @entity3 was observed.(ABSTRACT TRUNCATED AT 400 WORDS)

title: Serum XXXX in @entity3 and other thyroid disorders.

answer: @entity5


abstract: QUESTIONS UNDER STUDY: In this work we wanted to evaluate the effect of intra-articular injection (IAI) at the knee joint of 1 ml of Diprospan on the @entity3 . METHODS: Consecutive @entity0 attending the rheumatology or orthopaedic clinic with osteoarthritic knee @entity1 not responding satisfactorily to medical and physical therapy were asked to participate in our study. After consent, @entity0 had ultrasound-guided IAI of 1 ml of Diprospan, containing 2 mg of betamethasone sodium phosphate and 5 mg of betamethasone dipropionate. Demographic, clinical, laboratory and radiographic variables were documented. Just prior to the knee injection and 1, 2, 4 and 6 weeks later, @entity0 had a 1-  g @entity4 (ACTH) stimulation test. @entity2 ( @entity2 ) was defined as a poststimulation (30 minutes after ACTH injection) serum cortisol level of less than 18   g/dl (~500 nmol/l) and lack of a rise of >6   g/dl (~166 nmol/l) over the basal level in poststimulation serum cortisol. RESULTS: Twenty @entity0 completed the study. There were 3 male and 17 female @entity0 , with a mean age of 58.6    9.5 years. Six (30%) @entity0 had evidence of @entity2 and in five of them it was seen at one time-point, mostly at week 2 after the IAI. In one @entity0 , @entity2 was prolonged and observed from week 1 to week 4. CONCLUSIONS: IAI at the knee joint of 1 ml of Diprospan was associated with a transient high rate of @entity2 .

title: The effect of intra-articular injection of Diprospan at the knee joint on the XXXX .

answer: @entity3


abstract: OBJECTIVE: @entity4 ( @entity4 ) is a @entity1 with variable management strategies and prognosis. We aimed to analyze treatment modalities, prognostic factors and survival outcomes in @entity0 of @entity2 of EAC treated at our institution. METHODS: Forty-three @entity0 of @entity2 of EAC were analyzed for clinical presentation, stage, surgical procedures and radiotherapy (RT) modalities employed. Stell and McCormick staging system was used for staging of the @entity0 . Progression free survival (PFS) was estimated by the use of Kaplan-Meier product-limit method. Log rank test was used to assess the impact of prognostic variables on PFS. Multivariate analysis was performed using the Cox hazard regression model. p value of <0.05 was considered significant for all statistical analysis. RESULTS: Median age was 56 years (range: 12-84 years). Male to female ratio was 31:12. Stage was T1, T2 and T3 in 2, 17 and 18 @entity0 respectively. Sixteen @entity0 underwent surgery. Thirty-six @entity0 received RT (14 received definitive RT, 11 had post-operative RT and 11 had RT with palliative intent). Eight @entity0 (16%) received chemotherapy (5 received concurrent with RT, 2 had adjuvant and 1 had neo-adjuvant chemotherapy). Nine @entity0 (of 11 @entity0 ) achieved a @entity5 achieved a partial response (PR) after surgery plus post-operative RT. Nine @entity0 and 5 @entity0 respectively achieved CR and PR after definitive RT (with or without concurrent chemotherapy). Of the 11 @entity0 who received palliative RT, 2 had very good objective response (>50%) and 7 @entity0 had PR to palliative RT. After a median follow-up of 16 months, median PFS for the entire cohort was 14 months. Two-year PFS rates were 85.7%, 46.9% and 0% for @entity0 treated with surgery and post-operative RT, definitive RT and palliative RT respectively. On univariate analysis, higher stage (p=0.05) and @entity3 at presentation (p=0.0008) were significant predictors of inferior PFS. CONCLUSION: @entity0 with @entity4 present mostly in advanced stage at our centre. Combined higher stage (T3) and @entity3 at presentation portend poorer outcome. Combined modality treatment with surgery and radiotherapy should be advocated and palliative RT remains a reasonable treatment option in @entity0 with advanced incurable disease.

title: Treatment of squamous cell XXXX : A tertiary cancer centre experience.

answer: @entity4


abstract: The aim of this study was to correlate endoscopic, radiological and pathological observations in 30 @entity0 with @entity1 , with involvement of the stomach and/or duodenum. The incidence of gastroduodenal involvement in our @entity0 with @entity1 is about 3%. 22 of the 30 @entity0 had intrinsic lesions of the stomach and/or duodenum; in 8 @entity0 the lesions seemed to be produced by involvement from contiguous diseased bowel. Radiological studies and endoscopy of the gastroduodenal region are complementary. @entity2 . Other features, for example a diminished expansion and the presence of contiguity lesions, are better demonstrated by barium meal. The @entity7 found at endoscopy are heterogenous, but irregularly-shaped @entity5 and erosions in a disrupted mucosal pattern are typical for gastroduodenal @entity1 . Pathological examination of endoscopic "forceps"-biopsies permitted a conclusive diagnosis based on the presence of @entity4 , in 15/22 (68%) of the cases with @entity3 . This observation indicates that simple forceps biopsy is a very useful diagnostic tool. Involvement of the first part of the duodenum in @entity1 was complicated by a @entity6 in two @entity0 .

title: XXXX of the stomach and duodenum: A clinical study with emphasis on the value of endoscopy and endoscopic biopsies.

answer: @entity1


abstract: UNASSIGNED: Animal behavior can have profound effects on pathogen transmission and disease incidence. We studied the questing (= host-seeking) behavior of @entity2 ( @entity2 ) nymphs, which are the primary vectors of @entity1 in the eastern United States. @entity1 is common in northern but not in southern regions, and prior ecological studies have found that standard methods used to collect host-seeking nymphs in northern regions are unsuccessful in the south. This led us to hypothesize that there are behavior differences between northern and southern nymphs that alter how readily they are collected, and how likely they are to transmit the etiological agent of @entity1 to @entity0 . To examine this question, we compared the questing behavior of @entity2 nymphs originating from one northern ( @entity1 endemic) and two southern (non-endemic) US regions at field sites in Wisconsin, Rhode Island, Tennessee, and Florida. Laboratory-raised uninfected nymphs were monitored in circular 0.2 m2 arenas containing wooden dowels (mimicking stems of understory vegetation) for 10 (2011) and 19 (2012) weeks. The probability of observing nymphs questing on these stems (2011), and on stems, on top of leaf litter, and on arena walls (2012) was much greater for northern than for southern origin ticks in both years and at all field sites (19.5 times greater in 2011; 3.6-11.6 times greater in 2012). Our findings suggest that southern origin @entity2 nymphs rarely emerge from the leaf litter, and consequently are unlikely to contact passing @entity0 . We propose that this difference in questing behavior accounts for observed geographic differences in the efficacy of the standard sampling techniques used to collect questing nymphs. These findings also support our hypothesis that very low @entity1 incidence in southern states is, in part, a consequence of the type of host-seeking behavior exhibited by southern populations of the key @entity1 vector.

title: Different Populations of XXXX Nymphs Exhibit Differences in Questing Behavior That Have Implications for @entity0 Lyme Disease Risk.

answer: @entity2


abstract: UNASSIGNED: Animal behavior can have profound effects on pathogen transmission and disease incidence. We studied the questing (= host-seeking) behavior of @entity2 ( @entity2 ) nymphs, which are the primary vectors of @entity1 in the eastern United States. @entity1 is common in northern but not in southern regions, and prior ecological studies have found that standard methods used to collect host-seeking nymphs in northern regions are unsuccessful in the south. This led us to hypothesize that there are behavior differences between northern and southern nymphs that alter how readily they are collected, and how likely they are to transmit the etiological agent of @entity1 to @entity0 . To examine this question, we compared the questing behavior of @entity2 nymphs originating from one northern ( @entity1 endemic) and two southern (non-endemic) US regions at field sites in Wisconsin, Rhode Island, Tennessee, and Florida. Laboratory-raised uninfected nymphs were monitored in circular 0.2 m2 arenas containing wooden dowels (mimicking stems of understory vegetation) for 10 (2011) and 19 (2012) weeks. The probability of observing nymphs questing on these stems (2011), and on stems, on top of leaf litter, and on arena walls (2012) was much greater for northern than for southern origin ticks in both years and at all field sites (19.5 times greater in 2011; 3.6-11.6 times greater in 2012). Our findings suggest that southern origin @entity2 nymphs rarely emerge from the leaf litter, and consequently are unlikely to contact passing @entity0 . We propose that this difference in questing behavior accounts for observed geographic differences in the efficacy of the standard sampling techniques used to collect questing nymphs. These findings also support our hypothesis that very low @entity1 incidence in southern states is, in part, a consequence of the type of host-seeking behavior exhibited by southern populations of the key @entity1 vector.

title: Different Populations of @entity2 Nymphs Exhibit Differences in Questing Behavior That Have Implications for XXXX Lyme Disease Risk.

answer: @entity0


abstract: Herein, we report clinical, radiological, and follow-up results of seven cases of @entity2 and highlight the importance of rare and unusual properties of unusual locations of @entity2 . Seven @entity0 with @entity2 were treated in our institution (Antalya Memorial Hospital) between the period of February 2009 and March 2014 were reported. The @entity0 were classified according to the localization, symptomatology, and the presence of neurovascular involvement or organ compression. The results were discussed with the existing literature data. Five of our @entity0 had unusual symptomatology. Surgical excision was performed on six of seven @entity0 . One @entity0 was followed with scheduled outpatient visits alone. Our clinical follow-up results were good to excellent. In our case series, one @entity0 with clavicular involvement had impaired shoulder mechanic which resulted in @entity1 , while another with pubic ramus involvement had obstructive urination symptoms and @entity4 . One @entity0 with scapular involvement had snapping scapula symptoms, while two @entity0 with fibular head involvement had @entity3 and @entity3 symptoms in each. One @entity0 with ischial ramus involvement had sciatica, whereas another with first rib involvement had radiological evidences for subclavian @entity3 without any symptom. Based our experience, the flat bones which are usually ossified by intramembranous type of ossification during the fetal period (including the scapula, ilium, pubic ramus, ischium ramus, ribs and clavicle) are much less commonly affected and often have unusual symptoms. The @entity2 originating from the fibular head may seem innocent to an orthopedic surgeon. However, an orthopedic surgeon should be alert to tibiofibular @entity3 in this @entity0 population.

title: XXXX originating from unusual locations complicating orthopedic discipline: case series.

answer: @entity2


abstract: Microenvironment plays an important role in epithelial-mesenchymal transition (EMT) and @entity6 of cells in @entity3 ( @entity3 ). @entity8 ( @entity8 ) is known as a @entity0 @entity6 marker of @entity3 . To investigate the relationship between microenvironment and @entity6 , we performed an in  vitro co-culture assay. Four @entity3 cell lines (HepG2, Hep3B, @entity7 and @entity11 /PRF/5) were co-cultured with the TWNT-1 immortalized hepatic stellate cells (HSCs), which create a microenvironment with @entity3 . Cell proliferation ability was analyzed by flow cytometry (FCM) and @entity4 ( @entity2 ) assay, while migration ability was assessed by a wound healing assay. Expression of @entity8 was analyzed by immunoblotting and FCM. @entity3 cell lines were co-cultured with TWNT-1 treated with small interfering RNA (siRNA) for @entity5 and @entity12 ; we then analyzed proliferation, migration ability and protein expression using the methods described above. Proliferation ability was unchanged in @entity3 cell lines co-cultured with TWNT-1. Migration ability was increased in @entity3 cell lines (HepG2, Hep3B, @entity7 and @entity11 /PRF/5) directly (216.2  67.0, 61.0  22.0, 124.0  66.2 and 51.5  40.3%) and indirectly (102.5  22.0, 84.6  30.9, 86.1  25.7 and 73.9  29.7%) co-cultured with TWNT-1 compared with the @entity3 uni-culture. Immunoblot analysis revealed increased @entity8 expression in the @entity3 cell lines co-cultured with TWNT-1. Flow cytometry revealed that the population of @entity9 -/ @entity10 + and @entity8 -positive cells increased and accordingly, EMT and @entity6 in the @entity3 cell line were activated. These results were similar in the directly and indirectly co-cultured samples, indicating that humoral factors were at play. Conversely, @entity3 cell lines co-cultured with siRNA  -treated TWNT-1 showed decreased migration ability, a decreased population of @entity8 -positive and @entity9 -/ @entity10 + cells. Taken together, humoral factors secreted from TWNT-1 promote upregulation of @entity8 and EMT in @entity1 cells.

title: Hepatic stellate cells promote upregulation of XXXX and epithelial-mesenchymal transition in @entity1 cells.

answer: @entity8


abstract: Microenvironment plays an important role in epithelial-mesenchymal transition (EMT) and @entity6 of cells in @entity3 ( @entity3 ). @entity8 ( @entity8 ) is known as a @entity0 @entity6 marker of @entity3 . To investigate the relationship between microenvironment and @entity6 , we performed an in  vitro co-culture assay. Four @entity3 cell lines (HepG2, Hep3B, @entity7 and @entity11 /PRF/5) were co-cultured with the TWNT-1 immortalized hepatic stellate cells (HSCs), which create a microenvironment with @entity3 . Cell proliferation ability was analyzed by flow cytometry (FCM) and @entity4 ( @entity2 ) assay, while migration ability was assessed by a wound healing assay. Expression of @entity8 was analyzed by immunoblotting and FCM. @entity3 cell lines were co-cultured with TWNT-1 treated with small interfering RNA (siRNA) for @entity5 and @entity12 ; we then analyzed proliferation, migration ability and protein expression using the methods described above. Proliferation ability was unchanged in @entity3 cell lines co-cultured with TWNT-1. Migration ability was increased in @entity3 cell lines (HepG2, Hep3B, @entity7 and @entity11 /PRF/5) directly (216.2  67.0, 61.0  22.0, 124.0  66.2 and 51.5  40.3%) and indirectly (102.5  22.0, 84.6  30.9, 86.1  25.7 and 73.9  29.7%) co-cultured with TWNT-1 compared with the @entity3 uni-culture. Immunoblot analysis revealed increased @entity8 expression in the @entity3 cell lines co-cultured with TWNT-1. Flow cytometry revealed that the population of @entity9 -/ @entity10 + and @entity8 -positive cells increased and accordingly, EMT and @entity6 in the @entity3 cell line were activated. These results were similar in the directly and indirectly co-cultured samples, indicating that humoral factors were at play. Conversely, @entity3 cell lines co-cultured with siRNA  -treated TWNT-1 showed decreased migration ability, a decreased population of @entity8 -positive and @entity9 -/ @entity10 + cells. Taken together, humoral factors secreted from TWNT-1 promote upregulation of @entity8 and EMT in @entity1 cells.

title: Hepatic stellate cells promote upregulation of @entity8 and epithelial-mesenchymal transition in XXXX cells.

answer: @entity1


abstract: ETHNOPHARMACOLOGICAL RELEVANCE: Polyalthia longifolia var. pendula is a very popular herb in Bangladesh due to its traditional uses in treatment of @entity4 , @entity2 and @entity8 . The present study was conducted to investigate the antinociceptive activity of @entity5 extract of Polyalthia longifolia (EEPL) bark. MATERIALS AND METHODS: Hot plate and tail immersion tests, @entity7 -induced writhing test, @entity9 and @entity3 -induced paw licking tests in @entity0 were employed in this study. In all the experiments EEPL was administered orally at the doses of 50, 100 and 200mg/kg body weight. To investigate the possible participation of opioid system in EEPL-mediated effects, @entity6 was used to antagonize the action. RESULTS: EEPL showed a significant antinociceptive activity against both heat and chemical-induced nociception. The effects were dose-dependent and significant at the doses of 100 and 200mg/kg of EEPL. Besides, pretreatment with @entity6 caused significant inhibition of the antinociceptive activity induced by EEPL, revealing the possible involvement of the opioid receptors. CONCLUSION: These results indicate the antinociceptive activity of the bark of P. longifolia and support the ethnomedical use of this plant in treatment of different @entity1 .

title: Evaluation of antinociceptive activity of XXXX extract of bark ofPolyalthia longifolia.

answer: @entity5


abstract: BACKGROUND: @entity1 ( @entity3 ) is estimated to affect 10-15% of the adult population in the Caribbean. Preventive efforts require population wide measures to address its social determinants. We undertook a systematic review to determine current knowledge about the social distribution of @entity1 , its risk factors and major complications in the Caribbean. This paper describes our findings on the distribution by gender. METHODS: We searched Medline, Embase and five databases through the Virtual Health Library, for Caribbean studies published between 2007 and 2013 that described the distribution by gender for: known risk factors for Type 2 @entity3 , prevalence of @entity3 , and @entity3 control or complications. PRISMA guidance on reporting systematic reviews on health equity was followed. Only quantitative studies (n>50) were included; each was assessed for risk of bias. Meta-analyses were performed, where appropriate, on studies with a low or medium risk of bias, using random effects models. RESULTS: We found 50 articles from 27 studies, yielding 118 relationships between gender and the outcomes. @entity0 were more likely to have @entity3 , @entity2 , be less physically active but less likely to smoke. In meta-analyses of good quality population-based studies odds ratios for @entity0 vs. @entity0 for @entity3 , @entity2 and smoking were: 1.65 (95% CI 1.43, 1.91), 3.10 (2.43, 3.94), and 0.24 (0.17, 0.34). Three studies found @entity0 more likely to have better glycaemic control but only one achieved statistical significance. CONCLUSION AND IMPLICATIONS: Female gender is a determinant of @entity3 prevalence in the Caribbean. In the vast majority of world regions @entity0 are at a similar or lower risk of type 2 @entity1 than @entity0 , even when @entity2 is higher in @entity0 . Caribbean female excess of @entity1 may be due to a much greater excess of risk factors in @entity0 , especially @entity2 . These findings have major implications for preventive policies and research.

title: Female Gender Is a Social Determinant of XXXX in the Caribbean: A Systematic Review and Meta-Analysis.

answer: @entity1


abstract: BACKGROUND: Osteopathic medicine is based on a diagnostic and therapeutic system to treat tissue mobility/ motility dysfunctions in general, using different approaches (depending on the target tissue) known as osteopathic manipulative treatment. Among the available techniques those ones addressed to the cranial field are the most questioned because of the lack of scientific evidence; but the compression of the 4th ventricle technique has been largely studied in clinical trials. Studies have shown that the technique may affect both central and autonomous nervous system, modulating some reflexes (Traube-Hering baro signal), and modifying brain cortex electrical activity through central sensitization in subjects with @entity1 . Thus, investigators hypothesize that the compression of the 4th ventricle may modulate peak alpha frequency (eletroencephalographic assessment) and promote physical relaxation in subjects in vigil. METHODS/DESIGN: A randomized, controlled crossover trial with blinded assessor was designed to test the hypothesis. A total of 81 @entity0 will be assigned to three treatment conditions, with seven days of washout: (I) compression of the 4th ventricle; (II) sham compression of the fourth ventricle; (III) control (no intervention). The (I) power amplitude and the (II) frequencies of the dominant peak in the alpha band will be the primary outcome measures of the study. All @entity0 will be recruited at the Outpatient Rehabilitation Service of the University Hospital of Bras  lia - University of Bras  lia. All the electroencephalographic exams will be conducted by a blinded assessor. DISCUSSION: The investigators hypothesize that @entity0 with @entity1 submitted to the technique would have the peak alpha frequency modulated and, thus, would experience physical relaxation. TRIAL REGISTRATION: NCT02111382.

title: Immediate changes in electroencephalography activity in individuals with nonspecific XXXX after cranial osteopathic manipulative treatment: study protocol of a randomized, controlled crossover trial.

answer: @entity1


abstract: OBJECTIVE: @entity3 ( @entity3 ) occurs in 20-30% of @entity0 . The goal of this study is to assess the efficacy and safety of vagus nerve stimulation (VNS) in this group of @entity0 , including adult and pediatric populations and several off-label indications. METHODS: This is a retrospective review of 59 consecutive @entity0 in whom 60 VNS devices were implanted at a single institution during a 15-year period. @entity0 were evaluated in the @entity3 was performed. The series included indications not approved by the FDA, such as @entity0 under 12 years of age, pregnancy and right-sided VNS. Performing the procedure on an out- @entity0 basis was recently adopted, minimizing hospital length of stay. RESULTS: There were 42 adults and 17 @entity0 (14 under 12 years of age) and the mean age at implantation was 26 years. Duration of VNS therapy ranged from 6 months to 9 years. For the entire cohort, the mean percentage @entity4 reduction was 31.37%. Twenty @entity0 (34.48%) were considered responders ( @entity4 reduction >= 50%); 7 @entity0 (12.06%) had @entity4 reduction of >= 75% and 2 @entity0 had @entity4 control of >= 90% (3.4%). The @entity0 in whom right-sided VNS was implanted achieved the same reduction in @entity4 burden and the @entity0 who became pregnant could reduce antiepileptic drugs dosage, without complications. Side-effects were mild and there were no permanent @entity1 . One @entity0 died in the follow-up due to @entity2 previously known. CONCLUSIONS: VNS is a safe and effective palliative treatment for @entity3 @entity0 . There are an increasing number of indications and further randomized trials would potentially expand the number of @entity0 who may benefit from it. A multidisciplinary team is crucial for a complete preoperative evaluation and selection of the optimal candidates for the treatment.

title: Vagus nerve stimulation therapy for treatment-resistant XXXX : A 15-year experience at a single institution.

answer: @entity3


abstract: BACKGROUND: Despite the high @entity5 rates described in Latin America, @entity5 risk factors in poor urban settings are not well established. We investigated risk factors for @entity6 among Ecuadorian @entity0 . METHODS: A matched case-control study was carried out in a public hospital serving a coastal city. @entity0 with @entity6 were age- and sex-matched to non-asthmatics. A questionnaire was administered, and blood, as well as stool, and nasopharyngeal swabs were collected. RESULTS: Sixty cases and 119 controls aged 5-15 were evaluated. High proportions of cases were @entity7 with population-attributable fractions for @entity4 .5% for sIgE and 57.2% for SPT. Acute @entity5 risk increased with greater titers of mite IgE (3.51-50  kU/l vs. <0.70kU/l - OR 4.56, 95% CI 1.48-14.06, p  =  0.008; >50kU/l vs. <0.70kU/l - OR 41.98, 95% CI: 8.97-196.39, p  <  0.001). Asthma risk was significantly independently associated with @entity8 (adj. OR: 38.9, 95% CI 3.26-465), parental educational level (adj. OR 1.26, 95% CI: 1.08-1.46), and presence of sIgE (adj. OR: 36.7, 95% CI: 4.00-337), while a reduced risk was associated with current contact with pets (adj. OR: 0.07, 95% CI: 0.01-0.56). @entity2 was more frequent in cases (cases 35.6% vs. controls 7.8%, p  =  0.002). None of the cases were on maintenance therapy with inhaled @entity3 and most relied on emergency department for control. CONCLUSIONS: A high proportion of @entity0 presenting to a public hospital with @entity6 were @entity1 to mite, particularly at high IgE titer. Poor @entity5 control resulted in overuse of emergency care.

title: Risk factors for XXXX in tropical America: a case-control study in the City of Esmeraldas, Ecuador.

answer: @entity6


abstract: UNASSIGNED: In this study, we demonstrate the use of a genome-wide association mapping together with RNA-seq in a reduced number of samples, as an efficient approach to detect the causal mutation for a @entity1 . @entity5 is a recessive genodermatosis that manifests with neonatal mechanical fragility of the skin, blistering confined to the lamina lucida of the basement membrane and severe alteration of the hemidesmosomal junctions. In Spanish Churra @entity2 , @entity5 ( @entity5 ) has been detected in two commercial flocks. The @entity5 locus was mapped to @entity2 chromosome 11 by GWAS and subsequently fine-mapped to an 868-kb homozygous segment using the identical-by-descent method. The @entity6 , which is located within this region, was identified as the best positional and functional candidate gene. The RNA-seq variant analysis enabled us to discover a 4-bp deletion within exon 33 of the @entity6 gene ( @entity7 ). The @entity7 mutation causes a frameshift resulting in a premature stop codon at position 1472 of the integrin b4 protein. A functional analysis of this deletion revealed decreased levels of mRNA in @entity5 skin samples and the absence of integrin b4 labeling in immunohistochemical assays. Genotyping of @entity7 showed perfect concordance with the recessive mode of the disease phenotype. Selection against this causal mutation will now be used to solve the problem of @entity5 in flocks of Churra @entity2 . Furthermore, the identification of the @entity6 mutation means that affected @entity2 can be used as a large @entity0 animal model for the @entity0 form of @entity4 with @entity3 . Our approach evidences that RNA-seq offers cost-effective alternative to identify variants in the species in which high resolution exome-sequencing is not straightforward.

title: Combining GWAS and RNA-Seq Approaches for Detection of the Causal Mutation for Hereditary Junctional Epidermolysis Bullosa in XXXX .

answer: @entity2


abstract: UNASSIGNED: Purple sweet potato color (PSPC), @entity6 isolated from purple sweet potato, has been well demonstrated for the pharmacological properties. In the present study, we attempt to explore whether the antisenescence was involved in PSPC-mediated protection against endothelium dysfunction in @entity0 ( @entity0 ) and, if involved, what are the possible mechanisms. The results showed that atherogenesis and endothelial senescence in the thoracic aorta were promoted in @entity1 with @entity8 ; meanwhile, PSPC attenuated the deterioration of vascular vessel and inhibited the endothelial senescence. @entity0 is a documented high-risk factor for the development of @entity5 . Studies show that @entity7 ( @entity10 ) promotes endothelial cell senescence in vitro. In our study, we have determined that PSPC could suppress the @entity10 -induced premature senescence and the abnormal endothelial function, discovered in the early stages of @entity5 induced by @entity0 . We have discovered that the PSPC down-regulates reactive @entity2 species (ROS) accumulation and the @entity9 inflammasome functions. Furthermore, the premature senescence induced by @entity10 was inhibited after attenuation of ROS and deactivation of @entity9 inflammasomes. However, once the @entity9 inflammasomes are overactivated, PSPC could not restrain cell senescence. These data imply that the beneficial effects of PSPC on @entity0 -induced @entity4 and senescence are mediated through ROS and @entity9 signaling pathways, suggesting a potential target for the prevention of endothelial senescence-related @entity3 .

title: Purple sweet potato color inhibits endothelial premature senescence by blocking the XXXX inflammasome.

answer: @entity9


abstract: In fifteen subjects with oculo-cutaneous or ocular albinism pattern-reversal visual evoked potentials (VEP) were recorded to monocular whole-field (16 degrees radius) and right and left vertical half-field (16 degrees radius) stimulation from an array of occipital electrodes. In all 15 subjects the VEP was of low amplitude and the monocular response to whole-field stimulation showed abnormal asymmetry in scalp topography. This asymmetry was similar to that produced by stimulation of the temporal half-field in the same eye. Two distinct types of VEP asymmetry were readily identified in different subjects. In 5 the major positivity of the response ( @entity1 ) was distributed in the channels ipsilateral to the stimulated eye or temporal half-field, being similar in distribution to the @entity1 from the temporal hemifield or normal individuals. In 9 other subjects the converse occurred; the @entity1 was distributed contralaterally. The remaining subject was unique in that the responses from each eye had a distribution that resembled one of the two main groups. The nasal half-field responses also differentiated the two groups. On stimulation of the nasal field in the first group the @entity1 was usually absent or attenuated and when present it had the same topography as the temporal half-field @entity1 . In contrast the nasal half-field @entity1 from the second group was always present and, although almost invariably smaller than the temporal half-field @entity1 , it had an identical distribution. There was no correlation between these two patterns of VEP asymmetry and clinical or known genetic features. The findings confirm that in @entity0 albinos each hemisphere receives a predominantly monocular input from the contralateral eye; i.e. in addition to the temporal, half-field, approximately 20 degrees of the nasal half-field is projected to the hemisphere contralateral to each eye and not, as in normal subjects, to the ipsilateral hemisphere. Furthermore, the findings of two distinct and in some respects opposite types of VEP topographical asymmetry raises the possibility of two variants of the geniculo-cortical projection patterns existing in @entity0 albinos similar to those described in the Siamese cat.

title: Pattern evoked potentials in XXXX albinism. Evidence of two different topographical asymmetries reflecting abnormal retino-cortical projections.

answer: @entity0


abstract: UNASSIGNED: MicroRNAs (miRs) are a group of small non  -coding RNAs, which influence the development and progression of @entity1 by mediating the protein expression levels of @entity1 suppressors or oncogenes. @entity2 has been reported to be involved in the pathogenesis of @entity0 . However, its precise functions, and the mechanisms underlying these effects, remain to be elucidated. The present study demonstrated that @entity2 was markedly downregulated in @entity0 tissues and cell lines. The protein expression of Roundabout  1 ( @entity3 ) was negatively regulated by @entity2 in MCF  -7 @entity0 cells. Luciferase reporter assays identified @entity3 as a direct target of @entity2 in MCF  -7 cells. Additionally, upregulation of @entity2 inhibited MCF  -7 cell migration and invasion, which was attenuated by the restoration of the expression of @entity3 . Finally, it was shown that the expression of @entity3 mRNA and protein was increased in @entity0 tissues and cell lines. Therefore, it was hypothesized that @entity2 inhibits cell migration and invasion in @entity0 cells, at least in part, by directly targeting @entity3 . In conclusion, the present study highlights the importance of @entity2 and @entity3 in the progression of @entity0 .

title: MicroRNA  -29a inhibits cell migration and invasion by targeting Roundabout  1 in XXXX cells.

answer: @entity0


abstract: OBJECTIVE: We analyzed audiologic and surgical findings in @entity0 with @entity2 ( @entity2 ) with an intact tympanic membrane (TM) that was of a non-inflammatory origin. METHODS: We reviewed data from @entity0 who underwent exploratory tympanotomy for @entity2 with intact TM from January 1995 to November 2012. @entity0 with diseases of non-inflammatory origin were enrolled (69 @entity0 ; 79 ears). @entity0 were categorized into two groups: non- @entity1 (50 ears) and @entity1 (29 ears). Demographic data, intraoperative findings, and audiologic results were obtained and analyzed. RESULTS: Overall, the second decade was the most common age of diagnosis in both the non- @entity1 and @entity1 groups. Operative findings showed that @entity4 was more prevalent than @entity3 ; all @entity1 group subjects had @entity4 . Short columellization or partial ossicular replacement was the most frequently adopted surgical procedures in both groups. Overall, audiologically, air-conduction thresholds (ACs) and air-bone gaps were significantly improved over the short- and long-term period in both groups. However, the non- @entity1 group had significantly higher preoperative ACs than the @entity1 group, especially at low frequencies. CONCLUSION: This study provides clinicians with useful information regarding the clinical characteristics of @entity2 with intact TM of non-inflammatory origin.

title: Conductive XXXX with an intact tympanic membrane due to non-inflammatory causes.

answer: @entity2


abstract: The intramolecular proton transfer reaction of @entity1 in neon solvent has been investigated by mixed @entity0 ( @entity0 ) calculations and @entity0 ( @entity0 ) calculations. Comparing these calculated results with those for @entity1 in water reported in Part I [A. Yamada, H. Kojima, and S. Okazaki, J. Chem. Phys. 141, 084509 (2014)], the solvent dependence of the reaction rate, the reaction mechanism involved, and the quantum effect therein have been investigated. With @entity0 , the reaction rate in weakly interacting @entity2 is lower than that in strongly interacting water. However, with @entity0 , the order of the reaction rates is reversed. To investigate the mechanisms in detail, the reactions were categorized into three mechanisms: tunneling, thermal activation, and barrier vanishing. Then, the quantum and solvent effects were analyzed from the viewpoint of the reaction mechanism focusing on the shape of potential energy curve and its fluctuations. The higher reaction rate that was found for neon in @entity0 compared with that found for water solvent arises from the tunneling reactions because of the nearly symmetric double-well shape of the potential curve in neon. The thermal activation and barrier vanishing reactions were also accelerated by the zero-point energy. The number of reactions based on these two mechanisms in water was greater than that in neon in both @entity0 and @entity0 because these reactions are dominated by the strength of solute-solvent interactions.

title: A molecular dynamics study of intramolecular proton transfer reaction of XXXX in solution based upon a mixed quantum-classical approximation. II. Proton transfer reaction in non-polar solvent.

answer: @entity1


abstract: BACKGROUNDS/AIMS: Appropriate management for multifocal branch duct type @entity4 (BD-IPMNs) of the pancreas is still controversial. This study was intended to reveal surgical outcomes of surgical resection for multifocal BD-IPMNs, with @entity2 . METHODS: Between January 1995 and December 2013, 699 @entity0 underwent the pancreatic resection due to @entity2 in our institution. Among them, 37 @entity0 showed multifocal BD-IPMNs. After excluding @entity0 who had BD-IPMNs completely resected, medical records of 22 @entity0 with remained @entity2 were retrospectively reviewed. RESULTS: Mean @entity0 age was 65  6.4 years. Types of surgery included central pancreatectomy (n=1), distal pancreatectomy (n=14), and standard pylorus-preserving pancreaticoduodenectomy (n=7). Specimen pathology showed that IPMN was either at low/intermediate-grade @entity3 (n=17) or at high-grade @entity3 (n=2). Three @entity0 had IPMN associated with @entity1 . Their mean follow-up period was 40.4 months. During follow-up, one mortality occurred 35.2 months after the operation which was not associated with IPMN. There was no clinically significant disease progression or recurrence of IPMN in the remnant pancreas during the follow-up period. CONCLUSIONS: Our results support that we can safely preserve the @entity2 with multifocal BD-IPMNs. Benign-looking multifocal @entity2 do not affect the survival of @entity0 .

title: Surgical outcomes of multifocal branch duct XXXX of pancreas.

answer: @entity4


abstract: We present a rare case of functional @entity5 of the jejunal loop following left hepatectomy and hepaticojejunostomy long after pylorus-preserving pancreaticoduodenectomy (PPPD), which was successfully managed by @entity4 . A 70-year-old Korean @entity0 had undergone PPPD 6 years before due to 1.8 cm-sized distal @entity6 @entity1 . @entity7 led to diagnosis of recurrent @entity6 @entity1 mimicking perihilar @entity2 of type IIIb. After left portal vein embolization, the @entity0 underwent resection of the left liver and caudate lobe and remnant extrahepatic @entity6 . The pre-existing jejunal loop and choledochojejunostomy site were used again for new hepaticojejunostomy. The @entity0 recovered uneventfully, but clamping of the percutaneous transhepatic biliary drainage (PTBD) tube resulted in @entity3 . Biliary imaging studies revealed that biliary passage into the afferent jejunal limb was significantly impaired. We performed @entity4 of the afferent jejunal loop by using a 20 mm-wide balloon. Follow-up hepatobiliary scintigraphy showed gradual improvement in biliary excretion and the PTBD tube was removed at 1 month @entity4 . This very unusual condition was regarded as disuse atrophy of the jejunal loop, which was successfully managed by @entity4 and intraluminal keeping of a large-bore PTBD tube for 1 month.

title: Balloon dilation of jejunal afferent loop functional XXXX following left hepatectomy and hepaticojejunostomy long time after pylorus-preserving pancreaticoduodenectomy: a case report.

answer: @entity5


abstract: OBJECTIVE: Circulating @entity1 cells (CTCs) have known prognostic implications in metastatic castration-resistant @entity2 , but little is known regarding its utility in biochemical recurrence (BR) of @entity2 . The primary objectives were to determine whether CTCs are measurable in @entity0 with BR and whether it can reliably predict prostate-specific antigen (PSA) increase and PSA doubling times (PSADTs). METHODS: BR was identified in @entity0 after prostatectomy or radiation or both, with a PSA increase of  >=  0.2 for prior prostatectomy or > 2 mg/dL increase for post-nadir in prior radiotherapy. CTCs were enumerated at baseline at the time of study entry using the CellSearch (Janssen Diagnostics, Raritan, NJ) test. RESULTS: The median age for all 36 @entity0 accrued was 69.5 years (range, 51-91) with a median PSA of 1.65 ng/mL (range, 0.2-65.8). Gleason scores ranged from 5 to 9 (median, 7). The majority had prostatectomy (n  = 25), external beam radiotherapy (n  = 9), CyberKnife (Accuray, Sunnyvale, CA) (n  = 1), and combined radiohormonal therapy (n  = 1). PSADT ranged from 0.35 to 55 months, with a median of 7.43 months. The incidence of positive CTCs was 8.3% (3 @entity0 ), of whom 2 had biopsy-proven bony lesions on presenting with equivocal scans and PSADTs of 2.27 and 3.08 months, respectively. The third CTC-positive @entity0 had a PSADT of 4.99 months. CONCLUSIONS: Obtaining CTCs in unselected @entity0 presenting with BR has a relatively low yield. However, obtaining a positive CTC raises the suspicion of the presence of metastatic disease and may have utility for longitudinal follow-ups of @entity0 with BR.

title: Circulating @entity1 Cells in Biochemical Recurrence of XXXX .

answer: @entity2


abstract: OBJECTIVE: Circulating @entity1 cells (CTCs) have known prognostic implications in metastatic castration-resistant @entity2 , but little is known regarding its utility in biochemical recurrence (BR) of @entity2 . The primary objectives were to determine whether CTCs are measurable in @entity0 with BR and whether it can reliably predict prostate-specific antigen (PSA) increase and PSA doubling times (PSADTs). METHODS: BR was identified in @entity0 after prostatectomy or radiation or both, with a PSA increase of  >=  0.2 for prior prostatectomy or > 2 mg/dL increase for post-nadir in prior radiotherapy. CTCs were enumerated at baseline at the time of study entry using the CellSearch (Janssen Diagnostics, Raritan, NJ) test. RESULTS: The median age for all 36 @entity0 accrued was 69.5 years (range, 51-91) with a median PSA of 1.65 ng/mL (range, 0.2-65.8). Gleason scores ranged from 5 to 9 (median, 7). The majority had prostatectomy (n  = 25), external beam radiotherapy (n  = 9), CyberKnife (Accuray, Sunnyvale, CA) (n  = 1), and combined radiohormonal therapy (n  = 1). PSADT ranged from 0.35 to 55 months, with a median of 7.43 months. The incidence of positive CTCs was 8.3% (3 @entity0 ), of whom 2 had biopsy-proven bony lesions on presenting with equivocal scans and PSADTs of 2.27 and 3.08 months, respectively. The third CTC-positive @entity0 had a PSADT of 4.99 months. CONCLUSIONS: Obtaining CTCs in unselected @entity0 presenting with BR has a relatively low yield. However, obtaining a positive CTC raises the suspicion of the presence of metastatic disease and may have utility for longitudinal follow-ups of @entity0 with BR.

title: Circulating XXXX Cells in Biochemical Recurrence of @entity2 .

answer: @entity1


abstract: BACKGROUND: Data obtained from oral health surveys are very important for identifying disease-susceptible groups and for developing dental care and prevention programs. So, the purpose of the current article was to investigate the prevalence of @entity3 ( @entity3 ) in a population of Brazilian police. MATERIAL AND METHODS: Interviews and oral cavity examinations were performed on a sample of 395 police officers who were randomly selected by the calibrated researcher. The number of individuals was obtained by a sample calculation using the finite population correction. The diagnostic criteria were based on the WHO (1997) criteria and adapted to Brazilian surveys. RESULTS: In total, 8.61% of the population presented some OML. @entity1 and @entity5 ( @entity5 ) were the most prevalent lesions. CONCLUSIONS: The prevalence of potentially malignant disorders was lower than among the Brazilian population.The most prevalent lesion among the police officers was related to @entity1 . @entity0 dissatisfied with oral health had a higher risk of presenting @entity3 . Key words:Mouth @entity2 mucosa, military personnel, public health, oral pathology, @entity4 .

title: Prevalence of XXXX in a brazilian military police population.

answer: @entity2


abstract: BACKGROUND: Spinal anesthesia is widely used for caesarean section. Addition of intrathecal @entity5 to local anesthetics seems to improve the quality of block and prolong the duration of @entity2 . OBJECTIVES: The present study was designed to examine whether addition of intrathecal @entity5 enhances the analgesic efficacy of intrathecal @entity3 in @entity0 undergoing cesarean section. @entity0 AND METHODS: We conducted a randomized, prospective, double-blind, case-control, clinical trial. Eighty @entity0 were scheduled for cesarean section under spinal anesthesia. The @entity0 were randomly allocated to receive either 10 mg of hyperbaric @entity3 0.5% (control group) or 10 mg of hyperbaric @entity3 0.5% plus 50 mg @entity5 (case group) intrathecally. Hemodynamic variability, onset and duration of block and duration of @entity2 were evaluated. RESULTS: The onset of sensory blockade was delayed in case group compared with control group, and this was statistically significant. The onset of motor blockade had no difference in both groups. The duration of motor blockade was similar. Post-operative @entity2 was longer in @entity5 group but the difference was not meaningful. The intraoperative hemodynamic variability showed no significant differences between groups. CONCLUSIONS: This study showed that the addition of intrathecal @entity5 to @entity3 is not desirable in @entity0 undergoing cesarean section due to the delay in the onset of sensory blockade and the lack of significant effects of @entity4 on post-operative @entity1 .

title: Addition of Intrathecal @entity5 to XXXX for Spinal Anesthesia in Cesarean Section.

answer: @entity3


abstract: BACKGROUND: Spinal anesthesia is widely used for caesarean section. Addition of intrathecal @entity5 to local anesthetics seems to improve the quality of block and prolong the duration of @entity2 . OBJECTIVES: The present study was designed to examine whether addition of intrathecal @entity5 enhances the analgesic efficacy of intrathecal @entity3 in @entity0 undergoing cesarean section. @entity0 AND METHODS: We conducted a randomized, prospective, double-blind, case-control, clinical trial. Eighty @entity0 were scheduled for cesarean section under spinal anesthesia. The @entity0 were randomly allocated to receive either 10 mg of hyperbaric @entity3 0.5% (control group) or 10 mg of hyperbaric @entity3 0.5% plus 50 mg @entity5 (case group) intrathecally. Hemodynamic variability, onset and duration of block and duration of @entity2 were evaluated. RESULTS: The onset of sensory blockade was delayed in case group compared with control group, and this was statistically significant. The onset of motor blockade had no difference in both groups. The duration of motor blockade was similar. Post-operative @entity2 was longer in @entity5 group but the difference was not meaningful. The intraoperative hemodynamic variability showed no significant differences between groups. CONCLUSIONS: This study showed that the addition of intrathecal @entity5 to @entity3 is not desirable in @entity0 undergoing cesarean section due to the delay in the onset of sensory blockade and the lack of significant effects of @entity4 on post-operative @entity1 .

title: Addition of Intrathecal XXXX to @entity3 for Spinal Anesthesia in Cesarean Section.

answer: @entity5


abstract: 1. Certain muscles in the hind foot of @entity1 were partially paralysed by applying tetrodotoxin to part of their motor innervation. In these muscles motor nerve sprouting occurred from the terminals of the unblocked axons. The extent of sprouting was compared with that seen in totally paralysed and in partially denervated muscles. 2. Action potentials were blocked in the medial and lateral plantar nerves of adult @entity1 for 5-13 days by continuous superfusion with a solution containing @entity3 . The drug was delivered through a tube and nerve cuff from an osmotic pump placed intraperitoneally. Control experiments showed that @entity2 was complete and that signs of @entity0 were absent in the animals included in the study. 3. Two muscles (the second lumbrical and flexor digitorum brevis), which received innervation only from the medial plantar nerve, were totally paralysed by the @entity2 . Two different muscles (the fourth lumbrical and flexor digitorum quinti brevis) were only partially paralysed, since they received their innervation from the @entity5 and, in addition, from the sural nerve which was not blocked. One day before the final experiment, the @entity5 was cut, and its terminals degenerated. Thus in the partially paralysed muscles only the unblocked terminals from the sural nerve remained. These terminals were observed after staining with @entity6 and @entity4 . Similarly, terminals from the medial plantar nerve were examined in the totally blocked muscles from the same animal. 4. In other experiments, muscles were partially denervated by cutting the @entity5 in order to compare effects of @entity2 and nerve section. 5. Sprouting occurred under all three conditions. Active terminals in the muscles partially paralysed for 5-7 days sprouted to the same extent as terminals in muscles totally blocked during the same period: about 35% of the terminals had sprouts, and their average length was about 13 micron. Sprouting was more pronounced in partially denervated muscles: about 65% of the terminals had sprouts and they averaged 24 micron in length. Collateral (preterminal) sprouts were seen only after partial denervation. 6. Physiological and histological observations suggested that sprouts in paralysed muscles, unlike those in partially denervated muscles, seldom if ever made new synapses on neighbouring muscle fibres, even after 12-13 days of @entity2 . 7. The results show that inactive muscle fibres cause active nerve terminals on neighbouring fibres to sprout, perhaps by releasing a diffusible, sprout-promoting factor, which is part of the stimulus for motor nerve sprouting in partially denervated muscles.

title: Sprouting of active nerve terminals in partially inactive muscles of the XXXX .

answer: @entity1


abstract: BACKGROUND: @entity16 is a rare, inherited @entity2 caused by the accumulation of free @entity10 in lysosomes. It is treated by the administration of @entity15 , which should be monitored by trough white blood cell (WBC) @entity10 measurements to ensure effective treatment. CASE-DIAGNOSIS/TREATMENT: The index case had an older brother who had previously been diagnosed with @entity16 , allowing early diagnosis of the index case at the age of 5  months. @entity15 therapy was started at the age of 3  years; however, monitoring of WBC @entity10 levels did not occur on a regular basis during most of his life. @entity7 improved after correction of electrolyte disturbances, the initiation of @entity15 therapy and treatment with recombinant @entity0 growth hormone. Renal replacement therapy was started at the age of 11  years, and renal transplantation was performed at the age of 12  years. Extra-renal @entity10 accumulation caused multiple @entity12 (including @entity11 , @entity9 and @entity14 ), @entity1 , @entity13 owing to @entity4 and portal @entity3 due to nodular regenerative @entity8 , aggravated by @entity6 and partial portal vein @entity6 . The @entity0 died of diffuse @entity5 caused by severe portal @entity3 . CONCLUSION: @entity15 treatment should be started as early as possible, and dosage should be monitored and adapted based on trough WBC @entity10 levels. RELEVANT INTERNATIONAL GUIDELINE: Emma F et al. (2014) @entity16 : an international consensus document. Nephrol Dial Transplant 29:iv87-iv94.

title: Management dilemmas in pediatric nephrology: XXXX .

answer: @entity16


abstract: The liver is involved in a variety of critical biological functions including the homeostasis of @entity6 , @entity9 , @entity8 , and the synthesis of proteins that are secreted in the blood. It is also at the forefront in the detoxification of noxious metabolites that would otherwise upset the functioning of the body. As such, this vital component of the @entity0 system is exposed to a notable quantity of toxicants on a regular basis. It therefore comes as no surprise that there are over a hundred disparate @entity3 , encompassing such afflictions as @entity5 , @entity3 , and @entity2 . Most if not all of liver functions are dependent on energy, an ingredient that is primarily generated by the mitochondrion, the power house of all cells. This organelle is indispensable in providing @entity7 ( @entity7 ), a key effector of most biological processes. Dysfunctional mitochondria lead to a shortage in @entity7 , the leakage of deleterious reactive @entity1 species (ROS), and the excessive storage of fats. Here we examine how incapacitated mitochondrial bioenergetics triggers the pathogenesis of various @entity3 . Exposure of liver cells to detrimental environmental hazards such as oxidative stress, @entity4 , and various xenobiotics results in the inactivation of crucial mitochondrial enzymes and decreased @entity7 levels. The contribution of the latter to @entity3 and potential therapeutic cues to remedy these conditions are elaborated.

title: Dysfunctional mitochondrial bioenergetics and the pathogenesis of XXXX .

answer: @entity3


abstract: PURPOSE: The aim of this study was to demonstrate lipegfilgrastim superiority versus placebo in adults with @entity2 receiving myelosuppressive chemotherapy. METHODS: This phase III, double-blind study randomized chemotherapy-naive @entity0 to receive @entity1 and @entity4 with either lipegfilgrastim 6  mg or placebo. Because of the placebo control, @entity0 at individual high risk for @entity3 ( @entity3 ; >= 20%) were excluded. Study drug was administered on day 4 (24  h after chemotherapy) of a 21-day cycle for  <=4 cycles. Primary efficacy measure was @entity3 incidence in cycle 1. Secondary assessments included @entity3 ( @entity3 ), absolute neutrophil count (ANC) profile, and adverse events (AEs). RESULTS: The study included 375 @entity0 (lipegfilgrastim, n  =  250; placebo, n  =  125). Lipegfilgrastim superiority for @entity3 incidence in cycle 1 was not achieved but incidence was lower (2.4%) versus placebo (5.6%). Cycle 1 mean @entity3 was significantly shorter for lipegfilgrastim (0.6      1.1  days) versus placebo (2.3      0.5  days; p  <  0.0001). Incidence of severe @entity3 was significantly lower for lipegfilgrastim versus placebo overall and in each cycle (all, p  <  0.0001). Mean ANC nadir was lowest in cycle 1 but significantly higher for lipegfilgrastim (1.60      1.64) than placebo (0.67      0.85; p  <  0.0001). Mean time to ANC recovery was shorter with lipegfilgrastim in each cycle. Treatment-emergent AEs were similar between treatment groups. CONCLUSIONS: Lipegfilgrastim was not statistically superior to placebo for incidence of @entity3 in cycle 1, but was more effective in reducing incidence of severe @entity3 , @entity3 , and time to ANC recovery, with an acceptable safety profile. Controlled-trials.com identifier: ISRCTN55761467.

title: Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in @entity0 with XXXX receiving myelosuppressive therapy.

answer: @entity2


abstract: PURPOSE: The aim of this study was to demonstrate lipegfilgrastim superiority versus placebo in adults with @entity2 receiving myelosuppressive chemotherapy. METHODS: This phase III, double-blind study randomized chemotherapy-naive @entity0 to receive @entity1 and @entity4 with either lipegfilgrastim 6  mg or placebo. Because of the placebo control, @entity0 at individual high risk for @entity3 ( @entity3 ; >= 20%) were excluded. Study drug was administered on day 4 (24  h after chemotherapy) of a 21-day cycle for  <=4 cycles. Primary efficacy measure was @entity3 incidence in cycle 1. Secondary assessments included @entity3 ( @entity3 ), absolute neutrophil count (ANC) profile, and adverse events (AEs). RESULTS: The study included 375 @entity0 (lipegfilgrastim, n  =  250; placebo, n  =  125). Lipegfilgrastim superiority for @entity3 incidence in cycle 1 was not achieved but incidence was lower (2.4%) versus placebo (5.6%). Cycle 1 mean @entity3 was significantly shorter for lipegfilgrastim (0.6      1.1  days) versus placebo (2.3      0.5  days; p  <  0.0001). Incidence of severe @entity3 was significantly lower for lipegfilgrastim versus placebo overall and in each cycle (all, p  <  0.0001). Mean ANC nadir was lowest in cycle 1 but significantly higher for lipegfilgrastim (1.60      1.64) than placebo (0.67      0.85; p  <  0.0001). Mean time to ANC recovery was shorter with lipegfilgrastim in each cycle. Treatment-emergent AEs were similar between treatment groups. CONCLUSIONS: Lipegfilgrastim was not statistically superior to placebo for incidence of @entity3 in cycle 1, but was more effective in reducing incidence of severe @entity3 , @entity3 , and time to ANC recovery, with an acceptable safety profile. Controlled-trials.com identifier: ISRCTN55761467.

title: Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in XXXX with @entity2 receiving myelosuppressive therapy.

answer: @entity0


abstract: INTRODUCTION: Keratinization may be a vulnerable aid in predicting response to therapy for @entity3 . METHODS: The presence or absence of keratin in biopsy specimens was correlated with @entity2 behavior, locoregional control, patterns of failure, and survival of @entity0 irradiated for @entity3 . RESULTS: @entity0 with keratinizing @entity6 (World Health Organization [WHO] type 1) had a higher incidence (76%) of locally advanced @entity2 than those with nonkeratinizing (WHO type 2) and undifferentiated (WHO type 3) @entity2 (55%). The former group of @entity0 had a lower incidence (29%) of lymph node @entity1 than the later group (70%). @entity2 was controlled in 62% and neck nodes were controlled in 82% of all @entity0 . @entity2 control rates were 29% in @entity0 with keratinizing @entity6 and 79% in those with nonkeratinizing and undifferentiated @entity2 (P = .001). Nodal control rates were 76% for keratinizing squamous-cell @entity2 and 85% for nonkeratinizing and undifferentiated @entity2 (P = .001). The incidence of distant @entity1 was 6% in @entity0 with keratinizing squamous-cell @entity2 and 33% in those with nonkeratinizing and undifferentiated @entity2 (P = .001). @entity0 with keratinizing @entity6 , even though they had a lower incidence of lymphatic and distant @entity1 , had a poorer survival rate because of a higher incidence of @entity4 from uncontrolled @entity2 and nodal @entity1 . The 5-year survival rates were 35% for all @entity0 , 6% for those with keratinizing @entity6 , and 51% for nonkeratinizing and undifferentiated @entity2 respectively (P = .001). CONCLUSION: Higher doses of external beam radiotherapy with or without brachytherapy boost may be needed to improve local control and survival of @entity0 with keratinizing @entity5 of the nasopharynx, whereas an effective systemic therapy is needed for nonkeratinizing and undifferentiated @entity2 , which tend to metastasize.

title: Prognostic significance of keratinization in XXXX .

answer: @entity3


abstract: BACKGROUND: -Non-inducibility is frequently used as procedural endpoint of @entity3 ( @entity3 ) ablation after @entity2 ( @entity2 ). We investigated the influence of left ventricular (LV) function on the predictive value of non-inducibility for @entity3 recurrence and cardiac mortality. METHODS AND RESULTS: -Ninety-one @entity0 (82 @entity0 , 67  10 years) with @entity2 @entity3 underwent ablation between 2009 and 2012. Fifty-nine (65%) had a LV ejection fraction (EF) >30%, (mean 41  7) and 32 (35%) a LVEF <=30% (mean 20  5). Thirty @entity0 (51%) with EF>30% and 13 (41%) with EF <=30% were non-inducible after ablation (P=0.386). During a median follow-up of 23 (Q1-Q3 16-36) months, 35 @entity0 (38%) experienced @entity3 recurrences and 17 (18%) @entity1 . At one year follow-up, survival free from @entity3 recurrence and @entity1 for @entity0 with LVEF>30% was 80% (CI 95%, 70-90) compared to 42% (CI 95%, 33-51) for those with LVEF <=30% (P=0.001). Non-inducible @entity0 with LVEF>30% had a recurrence-free survival from @entity1 of 90% (CI 95%, 71-100) compared to 65% (CI 95% 47-83) for inducible @entity0 (P= 0.015). In the subgroup of @entity0 with LVEF <=30% the survival free from @entity3 recurrence and @entity1 was 31% (CI 95%, 0-60%) for non-inducible compared to 39% (CI 95%, 27-52) for those who remained inducible (P= 0.842). CONCLUSIONS: -Non-inducible @entity0 with moderately depressed LV function have a favorable outcome compared to @entity0 that remained inducible after ablation. On the contrary, @entity0 with severely depressed LV function have a poor prognosis independent of the acute procedural outcome.

title: Re-Assessing Non-Inducibility as Ablation Endpoint of Post-Infarction XXXX : The Impact of Left Ventricular Function.

answer: @entity3


abstract: Importance: Knowing the underlying etiology of @entity2 in @entity1 holds great promise for developing targeted treatments. Although successful preclinical studies and many positive clinical studies have been reported, it is unclear how many purported therapies have become established treatments. The quality of the clinical trials may be an important determinant for achieving clinical impact. Objective: To evaluate clinical impact, strengths, and weaknesses of clinical trials of diet or drug treatments to improve cognitive function in @entity0 with a @entity1 . Evidence Review: MEDLINE, EMBASE, PsycINFO, and Cochrane databases were searched from inception date to January 26, 2014, for clinical trials with cognitive outcomes in @entity0 with @entity1 . Outcome measures of @entity4 ( @entity4 ) were compared between trial registries and reports, and trials were evaluated for the quality of design using the Jadad score and Consolidated Standards of Reporting Trials (CONSORT) criteria. Findings: We identified 169 trial reports of 80 treatments for 32 @entity1 . Seventy-five trials (44.4%) reported potential efficacy, of which only 2 therapies are now established treatments, namely, dietary restriction for @entity3 and miglustat for @entity5 . The median sample size for @entity4 was 25 (range, 2-537). Only 30 of 107 @entity4 (28.0%) had acceptable Jadad scores exceeding 3. Reporting of key CONSORT items was poor. Reported outcome measures matched preregistered outcome measures in trial registries in only 5 of 107 @entity4 (4.7%). Conclusions and Relevance: The number of trials in the field of @entity1 is rapidly growing, but clinical impact has been limited because few drugs have become established treatments and the benefit of most drugs remains unclear. Most trials have small sample sizes and low quality of design. Predefinition of outcome measures, improved trial reporting and design, and international collaboration to increase recruitment are needed to unequivocally determine efficacy of drugs identified in preclinical research.

title: Treatment of Cognitive Deficits in XXXX : A Systematic Review of Clinical Trials of Diet and Drug Treatments.

answer: @entity1


abstract: @entity3 , a 21-residue peptide isolated from vascular endothelial cells, has a broad spectrum of actions. To clarify the involvement of @entity3 in acute @entity2 , we examined the effects of @entity3 and its receptor antagonist @entity5 on @entity4 -induced @entity2 in @entity1 . @entity1 were infused intravenously with heparin-saline (control), @entity3 (100 pmol/kg/hr), @entity4 (5 micrograms/kg/hr), or @entity4 plus @entity3 for 3.5 hr. In another experiment, @entity4 or @entity4 plus @entity5 (3 mg/kg/hr) was infused. Infusion of @entity4 caused @entity6 and @entity0 . @entity3 , when infused with @entity4 , decreased the extent of @entity0 with a significant increase in the pancreatic dry- to wet-weight ratio. Histological changes induced by @entity4 were markedly attenuated when @entity3 was given with @entity4 . In contrast, endothelin-receptor blockade with @entity5 further augmented @entity0 caused by @entity4 . The extent of inflammatory cell infiltration was greater than @entity5 was given with @entity4 . @entity3 or @entity5 had no influence on @entity6 . This study suggests that @entity3 has protective effects on experimental acute @entity2 .

title: Protective effects of @entity3 on acute XXXX in @entity1 .

answer: @entity2


abstract: @entity3 , a 21-residue peptide isolated from vascular endothelial cells, has a broad spectrum of actions. To clarify the involvement of @entity3 in acute @entity2 , we examined the effects of @entity3 and its receptor antagonist @entity5 on @entity4 -induced @entity2 in @entity1 . @entity1 were infused intravenously with heparin-saline (control), @entity3 (100 pmol/kg/hr), @entity4 (5 micrograms/kg/hr), or @entity4 plus @entity3 for 3.5 hr. In another experiment, @entity4 or @entity4 plus @entity5 (3 mg/kg/hr) was infused. Infusion of @entity4 caused @entity6 and @entity0 . @entity3 , when infused with @entity4 , decreased the extent of @entity0 with a significant increase in the pancreatic dry- to wet-weight ratio. Histological changes induced by @entity4 were markedly attenuated when @entity3 was given with @entity4 . In contrast, endothelin-receptor blockade with @entity5 further augmented @entity0 caused by @entity4 . The extent of inflammatory cell infiltration was greater than @entity5 was given with @entity4 . @entity3 or @entity5 had no influence on @entity6 . This study suggests that @entity3 has protective effects on experimental acute @entity2 .

title: Protective effects of XXXX on acute @entity2 in @entity1 .

answer: @entity3


abstract: @entity3 , a 21-residue peptide isolated from vascular endothelial cells, has a broad spectrum of actions. To clarify the involvement of @entity3 in acute @entity2 , we examined the effects of @entity3 and its receptor antagonist @entity5 on @entity4 -induced @entity2 in @entity1 . @entity1 were infused intravenously with heparin-saline (control), @entity3 (100 pmol/kg/hr), @entity4 (5 micrograms/kg/hr), or @entity4 plus @entity3 for 3.5 hr. In another experiment, @entity4 or @entity4 plus @entity5 (3 mg/kg/hr) was infused. Infusion of @entity4 caused @entity6 and @entity0 . @entity3 , when infused with @entity4 , decreased the extent of @entity0 with a significant increase in the pancreatic dry- to wet-weight ratio. Histological changes induced by @entity4 were markedly attenuated when @entity3 was given with @entity4 . In contrast, endothelin-receptor blockade with @entity5 further augmented @entity0 caused by @entity4 . The extent of inflammatory cell infiltration was greater than @entity5 was given with @entity4 . @entity3 or @entity5 had no influence on @entity6 . This study suggests that @entity3 has protective effects on experimental acute @entity2 .

title: Protective effects of @entity3 on acute @entity2 in XXXX .

answer: @entity1


abstract: IMPORTANCE: Little information is available on the long-term clinical outcome of @entity0 with @entity4 ( @entity4 ). OBJECTIVE: To assess the incidence rates of @entity3 , @entity4 events, and mortality in a large international cohort of @entity0 with @entity4 . DESIGN, SETTING, AND @entity0 : A prospective cohort study was conducted beginning May 2, 2008, and completed January 30, 2014, at hospital-based centers specialized in the management of @entity5 ; a 2-year follow-up period was completed January 30, 2014, and data analysis was conducted from July 1, 2014, to February 28, 2015. @entity0 included 604 consecutive @entity0 with objectively diagnosed @entity4 ; there were no exclusion critieria. Information was gathered on baseline characteristics, risk factors, and antithrombotic treatment. Clinical outcomes during the follow-up period were documented and reviewed by a central adjudication committee. MAIN OUTCOMES AND MEASURES: Major @entity3 , defined according to the International Society on @entity4 and Hemostasis; @entity3 requiring hospitalization; @entity4 events, including venous and arterial @entity4 ; and all-cause mortality. RESULTS: Of the 604 @entity0 (median age, 54 years; 62.6% males), 21 (3.5%) did not complete follow-up. The most common risk factors for @entity4 were @entity6 (167 of 600 @entity0 [27.8%]) and solid @entity1 (136 of 600 [22.7%]); the most common sites of @entity4 were the portal vein (465 of 604 [77.0%]) and the mesenteric veins (266 of 604 [44.0%]). Anticoagulation was administered to 465 @entity0 in the entire cohort (77.0%) with a mean duration of 13.9 months; 175 of the anticoagulant group (37.6%) received parenteral treatment only, and 290 @entity0 (62.4%) were receiving @entity7 antagonists. The incidence rates (reported with 95% CIs) were 3.8 per 100 @entity0 -years (2.7-5.2) for major @entity3 , 7.3 per 100 @entity0 -years (5.8-9.3) for @entity4 events, and 10.3 per 100 @entity0 -years (8.5-12.5) for all-cause mortality. During anticoagulant treatment, these rates were 3.9 per 100 @entity0 -years (2.6-6.0) for major @entity3 and 5.6 per 100 @entity0 -years (3.9-8.0) for @entity4 events. After treatment discontinuation, rates were 1.0 per 100 @entity0 -years (0.3-4.2) and 10.5 per 100 @entity0 -years (6.8-16.3), respectively. The highest rates of major @entity3 and @entity4 events during the whole study period were observed in @entity0 with @entity2 (10.0 per 100 @entity0 -years [6.6-15.1] and 11.3 per 100 @entity0 -years [7.7-16.8], respectively); the lowest rates were in @entity0 with @entity4 secondary to transient risk factors (0.5 per 100 @entity0 -years [0.1-3.7] and 3.2 per 100 @entity0 -years [1.4-7.0], respectively). CONCLUSIONS AND RELEVANCE: Most @entity0 with @entity4 have a substantial long-term risk of @entity4 events. In @entity0 with @entity2 , this risk must be balanced against a similarly high risk of major @entity3 . Anticoagulant treatment appears to be safe and effective in most @entity0 with @entity4 .

title: Long-term Clinical Outcomes of XXXX : Results of an International Registry.

answer: @entity4


abstract: BACKGROUND: Determining @entity2 ( @entity2 ) is of paramount importance after @entity5 ( @entity5 ), although its accuracy depends upon the reliability of the neurologic examination. Here, we determine if anatomic location of cervical @entity5 by MRI (MRI level of injury) can predict @entity2 in the acute traumatic setting. METHODS: A retrospective review was undertaken of @entity5 @entity0 with macroscopic evidence of cervical @entity5 from non-penetrating @entity3 , all of whom had undergone cervical spine MRI and complete neurologic testing. The recorded MRI information included cord lesion type (intra-axial @entity1 , @entity4 ) and MRI locations of upper and lower lesion boundary, as well as lesion epicenter. Pearson correlation and Bland-Altman analyses were used to assess the relationship between MRI levels of @entity3 . RESULTS: All five MRI parameters, namely (1) upper and (2) lower boundaries of cord @entity1 , (3) lesion epicenter, and (4) upper and (5) lower boundaries of cord @entity4 demonstrated statistically significant, positive correlations with @entity2 . The MRI locations of upper and lower boundary of @entity4 were found to have the strongest correlation with @entity2 (r = 0.72 and 0.61, respectively; p < 0.01). A weaker (low to moderate) correlation existed between lower boundary of cord @entity1 and @entity2 (r = 0.30; p < 0.01). Upper boundary of cord @entity4 on MRI demonstrated the best agreement with @entity2 (mean difference 0.03    0.73; p < 0.01) by Bland-Altman analysis. CONCLUSIONS: MRI level of injury has the potential to serve as a surrogate for @entity2 in instances where the neurologic examination is either unavailable or unreliable.

title: Can anatomic level of injury on MRI predict neurological level in acute cervical XXXX ?

answer: @entity5


abstract: UNASSIGNED: @entity0 with @entity4 may have insufficientenergy substrates, due to @entity2 and @entity3 , which adversely affects the prognosis. Hyperlipidaemia has been reported to be associated with @entity4 and to represent a significant prognostic factor for survival in @entity4 . The aim of this study was to examine the prevalence of dyslipidaemia among a cohort of @entity0 with @entity4 and how the lipid profile of @entity0 with @entity4 influenced the prognosis. This was a prospective observational cohort study comprising 512 @entity4 @entity0 , recruited for the @entity6 ( @entity6 ) investigational medicinal product trial. @entity5 serum concentrations of total @entity1 (TC), low density lipoprotein @entity1 (LDL-C) and high density lipoprotein @entity1 (HDL-C) were measured as part of routine monitoring in the trial. Seventy-three percent of the @entity0 had hypercholesterolaemia (defined as total @entity1 >=  5.1 mmol/l) at the screening visit. The prevalence of hypercholesterolaemia decreased with time and was 64% at 18 months follow-up. On unadjusted analysis total @entity1 , LDL-C and LDL/HDL ratio had a statistically significant effect on survival (p = 0.015, 0.003 and 0.027, respectively). When adjusted for prognostic covariates, however, none of the lipid measures was found to have a statistically significant effect on survival. In conclusion, prognosis in @entity4 is not influenced by the lipid profile of @entity0 .

title: Effect of lipid profile on prognosis in the @entity0 with amyotrophic lateral sclerosis: Insights from the XXXX clinical trial.

answer: @entity6


abstract: UNASSIGNED: @entity0 with @entity4 may have insufficientenergy substrates, due to @entity2 and @entity3 , which adversely affects the prognosis. Hyperlipidaemia has been reported to be associated with @entity4 and to represent a significant prognostic factor for survival in @entity4 . The aim of this study was to examine the prevalence of dyslipidaemia among a cohort of @entity0 with @entity4 and how the lipid profile of @entity0 with @entity4 influenced the prognosis. This was a prospective observational cohort study comprising 512 @entity4 @entity0 , recruited for the @entity6 ( @entity6 ) investigational medicinal product trial. @entity5 serum concentrations of total @entity1 (TC), low density lipoprotein @entity1 (LDL-C) and high density lipoprotein @entity1 (HDL-C) were measured as part of routine monitoring in the trial. Seventy-three percent of the @entity0 had hypercholesterolaemia (defined as total @entity1 >=  5.1 mmol/l) at the screening visit. The prevalence of hypercholesterolaemia decreased with time and was 64% at 18 months follow-up. On unadjusted analysis total @entity1 , LDL-C and LDL/HDL ratio had a statistically significant effect on survival (p = 0.015, 0.003 and 0.027, respectively). When adjusted for prognostic covariates, however, none of the lipid measures was found to have a statistically significant effect on survival. In conclusion, prognosis in @entity4 is not influenced by the lipid profile of @entity0 .

title: Effect of lipid profile on prognosis in the XXXX with amyotrophic lateral sclerosis: Insights from the @entity6 clinical trial.

answer: @entity0


abstract: BACKGROUND: Several randomized trials have tested the use of @entity4 ( @entity4 ) and @entity6 ( @entity6 ) in relieving chemotherapy-induced @entity3 . However, the use of CSFs in the treatment of @entity2 remains virtually unexplored. PURPOSE: This study evaluated the benefits of adding CSF therapy to the standard antibiotic treatments given to @entity1 @entity0 for chemotherapy-induced @entity2 . The usefulness of CSFs was quantified in terms of reducing the following: (a) the duration of @entity5 , (b) the length of hospitalization, and (c) the overall cost of the treatment. METHODS: A randomized trial was conducted to test whether the administration of either @entity4 or @entity6 improved the outcome of standard antibiotic therapy ( @entity8 plus @entity7 ) in nonleukemic @entity1 @entity0 with @entity2 (> 38 degrees C) and grade IV @entity5 (absolute neutrophil count [ANC] < 500/mm3) induced by standard-dose chemotherapy. Of 121 @entity0 who entered the trial, 39 received @entity4 (5 micrograms/kg body weight per day), 39 received @entity6 (5 micrograms/kg body weight per day), and 43 received a placebo beginning just after the first dose of antibiotics. Treatments were continued for at least 5 days (7 days with clinically or microbiologically documented infections) or until 2 days after @entity2 subsided and ANCs rose above 1000/mm3. RESULTS: The median duration of grade IV @entity5 (ANC of < 500/mm3) was 2 days in both CSF arms and 3 days in the placebo arm (P < .001). The median duration of @entity5 with an ANC of less than 1000/mm3 was also significantly shorter in @entity0 receiving @entity4 or @entity6 (P < .001). The median duration of @entity2 was similar in the three arms. The median hospital stay was 5 days (range, 5-14 days) in the @entity4 arm, 5 days (range, 5-10 days) in the @entity6 arm, and 7 days (range, 5-34 days) in the placebo arm (P < .001). The median time on CSF was 4 days in both treatment arms. The mean cost of overall treatment was reduced by  1300- 1400 in the CSF arms compared with the placebo arm (P = .11 for @entity4 versus placebo; P = .06 for @entity6 versus placebo; P = .7 for @entity4 versus @entity6 ). CONCLUSIONS: Adding @entity4 or @entity6 therapy to antibiotic treatment shortens the duration of @entity5 and the duration of hospitalization in @entity0 with @entity2 . A statistically nonsignificant trend toward lower cost was observed in the CSF arms as compared with the placebo arm. IMPLICATIONS: The benefits of CSFs to @entity1 @entity0 with chemotherapy-induced @entity2 merit further evaluation in large randomized trials.

title: Improving treatment of chemotherapy-induced XXXX by administration of colony-stimulating factors.

answer: @entity2